News - EGFR exon 19 deletion + EGFR S768I

4years

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. (PubMed, Oncologist)

Afatinib treatment at 40 mg daily is associated with high rates of adverse events and dose reductions; alternative strategies including pulse intermittent dosing should be evaluated prospectively. Osimertinib (with favorable safety profile and intracranial penetration) has shown promising results in this population in a phase II trial from South Korea; additional trials are ongoing.

4 years ago

Clinical • Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR L858R + EGFR T790M • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719X + EGFR S768I • EGFR L861Q + EGFR G719X • EGFR L858R + EGFR exon 19 deletion • EGFR T790M + KRAS mutation • EGFR mutation + EGFR T790M • EGFR G719A + EGFR S768I • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I • EGFR T790M + exon 19 deletion

Tagrisso (osimertinib) • Gilotrif (afatinib)

4years

Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib. (PubMed, Tokai J Exp Clin Med)

Treatment with afatinib (40 mg/day) produced a partial response, which was maintained for 17 months with continued treatment. A literature review revealed that lung cancer with G719X/S768I compound mutation exhibited good response to EGFR-TKIs, even better than that of lung cancers with single uncommon mutations.

4 years ago

Clinical • Review • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I • EGFR L861Q + EGFR G719X • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I

Gilotrif (afatinib)

over4years

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). (PubMed, J Clin Oncol)

Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

over 4 years ago

Clinical • P2 data • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR L858R + EGFR T790M • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I • EGFR L861Q + EGFR G719X • EGFR L858R + EGFR exon 19 deletion • EGFR mutation + EGFR T790M • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I • EGFR T790M + exon 19 deletion

Tagrisso (osimertinib)

over4years

High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC. (PubMed, Cancer Rep (Hoboken))

The shorter survival of patients with the S768I SNV predicts aggressive disease and poor prognosis as a result of this mutation. Studies in larger cohorts and/or animal models are necessary to confirm these findings.

over 4 years ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR exon 19 deletion • EGFR S768I • EGFR exon 19 deletion + EGFR S768I

over4years

TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically-relevant EGFR mutations. (PubMed, Mol Cancer Res)

Lung cancer and genetically engineered cell lines, as well as murine xenograft models were used to evaluate the efficacy of TAS6417 and other approved/in-development EGFR TKIs (erlotinib, afatinib, osimertinib, and poziotinib). Taken together, we demonstrate that TAS6417 is a potent EGFR TKI with a broad spectrum of activity and a wider therapeutic window than most approved/in-development generations of EGFR inhibitors. Implications: TAS6417/CLN-081 is a potent EGFR TKI with a wide therapeutic window and may be effective in lung cancer patients with clinically relevant EGFR mutations.

over 4 years ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR L858R + EGFR T790M • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR G719X + EGFR S768I • EGFR L861Q + EGFR G719X • EGFR L858R + EGFR exon 19 deletion • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I • EGFR T790M + exon 19 deletion

Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • Pozenveo (poziotinib) • zipalertinib (CLN-081)

over4years

[VIRTUAL] Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia. (ASCO 2020)

"Uncommon, potentially actionable EGFR mutations were found in 9% of plasma samples from East Asian NSCLC patients. In this clinical practice dataset, uncommon EGFR mutations were more prevalent than actionable biomarkers in other genes. These data support the use of NGS testing methods to identify NSCLC patients for appropriate EGFR-targeted therapy."

over 4 years ago

Clinical

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • RET fusion • MET exon 14 mutation • EGFR L861Q • MET mutation • EGFR S768I • EGFR positive • EGFR G719A • EGFR L718Q • EGFR L858R + EGFR exon 19 deletion • EGFR G719A + EGFR S768I • EGFR L858R + EGFR S768I • EGFR exon 19 deletion + EGFR S768I

Guardant360® CDx